OptimizeRx Corp. announced organizational updates and leadership advancements designed to accelerate its 'Rule of 40' strategy, which balances sustained growth with increased profitability. These changes reflect CEO Steve Silvestro's commitment to aligning talent with strategic objectives.
Key advancements include Ed Stelmakh appointed Chief Financial & Strategic Officer (CFSO), expanding his role to encompass corporate strategy alongside financial leadership. Theresa Greco, Chief Commercial Officer (CCO), will focus on the growth plan and transitioning to a recurring revenue model.
Other leadership changes include Marion Odence-Ford as Chief Legal & Administrative Officer (CLAO), Doug Besch as Chief Product & Technology Officer (CPTO) leading data and partnership efforts, Brendan Merrell as Chief Operating Officer (COO), and Andy D’Silva promoted to Chief Business Officer (CBO) focusing on strategic planning and investor relations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.